Marketecture: Get Smart. Fast.

Episode 141: The State of Pharma Advertising with Josh Walsh of BranchLab
Date: September 26, 2025
Host: Ari Paparo
Co-host: Eric Franchi
Guest: Josh Walsh, CEO and Founder, BranchLab

Episode Overview

This episode explores the pivotal transformations underway in pharma advertising. Ari Paparo and Eric Franchi dive into the week's major ad tech news—Google’s antitrust trial, advances in AI, major industry M&A, and Nvidia's game-changing AI investments—before a deep-dive interview with Josh Walsh, CEO of BranchLab. The discussion with Josh unpacks the technical and regulatory challenges in pharma marketing, the evolution of privacy-safe targeting, and the implications of recent legislative moves.

Key Segment Breakdown & Timestamps

1. Industry News Discussion

[00:00–31:37]

a. Google Antitrust Trial—Live from Arlington

• Vibe of the Trial: Less about guilt/innocence and more a “dysfunctional negotiation” on remedies after Google already judged a monopoly.
  • Ari: “This is not a trial about guilt or innocence... It’s like a really dysfunctional negotiation.” [04:00]
  • Judge Brinkomash’s running joke: "My two favorite words in English language: 'Are we settled?'" [05:54]
• Divestiture Scenarios: Conflicting witness testimonies about what should be spun out (e.g., ADX, DFP); buyers lining up.
  • Ari: “I could run the ad exchange. There’s probably like, there’s a ridiculous number of companies who would want to bid on this thing.” [08:02]
• DV360 Revenue Insights:
  • New evidence shared showing DV360 spends $450M/month on display, ~$800M/month on YouTube, making DV360 primarily a YouTube buying platform. [09:00]
  • Comparison: Trade Desk estimated at $7–8B annual spend; DV360 (including YouTube) at ~$15B annually. [11:04]

b. Google & Browser AI Innovations

• AI in Chrome:
  • New Gemini integration and agentic features—browser acts as an assistant, booking services on your behalf. [12:49]
  • Ari: “The idea of an AI powered browser is really exciting for me... I think it could actually be good for publishers.” [12:49]
• Long-term Impact:
  • How AI agentic browsing could change web and publisher interaction models. [13:50]
  • Eric: “That’s a really neat perspective... will this be Chrome and Google owning it... or something ubiquitous?” [14:53]

c. Ben Thompson: Google’s AI Future in Video

• Stratechery’s Take:
  • Google’s AI edge may be in YouTube, not chatbots—using AI for shoppable moments and creative tools. [16:06]
  • Ari: “I don’t think we’ve seen the end of innovation in the format of video people experience.” [17:54]

d. IAS Goes Private

• IAS Acquisition by Novacap: $1.9B buyout (22% premium), following a trend of taking “legacy” measurement firms private for AI-centric retooling. [19:33]
  • Ari: “Was there something that needed to be done to the company, structurally, that was so big you couldn’t do it as a public company?” [20:55]
  • Eric: “Take the thing private. Really retool this for the AI era, likely do some acquisitions.” [22:00]
• Strategic Outlook:
  • Ari’s playbook: “Sell Publica for $500M... Or double down on measurement and buy Kantar, Nielsen, Comscore.” [23:44]

e. New TTD & Axiom Partnership

• True Intelligence—live UID2-based feedback loop, aiming to bring walled garden-level measurement to the open web. [26:23]

f. Nvidia–OpenAI’s Monumental Deal

• Nvidia Invests $100B in OpenAI:
  • Revenue commitments and equity upside—a power play in compute supply for the AI era. [27:41]
  • Ari: “It’s like Web 1.0 all over again… when the tide goes down, when the music stops... it’s not the best.” [29:02]

2. Featured Interview: Josh Walsh (BranchLab)

[31:37–51:56]

a. BranchLab’s Mission & Technology [32:03]

• Privacy-Safe Health Data Targeting:
  • BranchLab uses neural networks trained on health data to predict outcomes using non-health data—avoiding PII and meeting HIPAA/state regs.
  • Josh: “We’re training different types of neural networks… to predict health outcomes in non health data. It’s a privacy-forward way of activating against healthcare audiences.” [32:05]
  • Leverages demographic, psychographic, firmographic data to mimic traditional health segment performance—without exposing raw health info. [32:36]
  • Key regulatory challenges: new state laws (WA’s “My Health My Data,” NY’s S929), which heavily restrict how health audience data can be deployed. [33:11]

b. Strategic Funding from Lance Armstrong & Next Ventures [34:09]

• Origin Story: Investment came via a direct outreach from Lance Armstrong (“I had to check it wasn’t a bot”).
  • Lance’s Next Ventures sees BranchLab as part of “transforming the US Healthcare system from sick care to proactive care.”
  • Process: “We met Monday, deal was closed Friday.” [34:09]
  • Ari jokes: “Would you say it was a big step up from Aperium giving you money?” Josh: “It’s a lateral step, you know… one plus one equals three.” [36:47]
  • Lighthearted moment about joining Lance on a bike ride and potential for having Armstrong as a Marketecture keynote. [37:10–38:34]

c. Deep Intent’s $637M PE Buyout—Pharma DSP Valuation Context [39:26]

• Congrats from a “non-competitor”:
  • Josh: “We partner with Deep Intent... a lot of our customers deploy BranchLab-powered audiences on their DSP.” [39:26]
  • Industry insight: “This is a huge, specially regulated, hyper specific market that requires specialized tools, and Deep Intent at that valuation is more proof of that.” [39:55]

d. Why Pharma Advertising Needs Niche Solutions [41:07]

• Not Just Data, but Activation Rules:
  • BranchLab delivers models, not audience data, so clients can use their own CRMs without violating new privacy laws.
  • Complex state-level regulation means standard audience matching (even pseudonymized) is increasingly risky or non-compliant.
  • Josh: “The legacy way of sending health audiences is prohibited in [WA state]... probably prohibited in other states.” [42:40]
  • “We lock hyper-regulated data behind a neural net, never let it in or out, and instead just deploy lightweight probability models.” [44:03]

e. The Federal Government & the Specter of a Pharma Ad Ban [45:14]

• Bipartisan Issue, but Not Likely to Result in a Ban:
  • More likely to see increased regulation or requirements for side-effects disclosures than an outright ban.
  • Josh: “This administration is taking on what really is a bipartisan winning issue, which is, how can we better fight for the patient/consumer.” [45:14]
  • Ari: “It sounds like they’re trying to get a political win here, regardless of whether it really moves the ball forward that much.” [46:17]
  • New proposals might tweak creative/messaging and close loopholes, but legal and First Amendment precedent make true bans unlikely. [47:45]

f. Prediction: Heightened Regulation, Technology-Led Privacy

• Federal preemption possible—a move to a single, national standard from growing patchwork of state rules.
• Importance of privacy-by-design: “When done responsibly, advertising can be one of the most powerful tools for improving public health... it equals more doctor visits. Health outcome improves mathematically.” [49:52]
• “If it requires regulations to ensure… the industry does that, I applaud it. I hope that doesn’t need to happen. In my opinion, privacy by design technology can solve this problem very quickly versus having to wait for things to be settled in the courts.” [51:18]

Memorable Closing

Ari: “Stop doomscrolling on WebMD and asking ChatGPT why your hip hurts. Just ask your doctor.” [51:38]

Notable Quotes & Moments

• On the dysfunction of the Google trial:
  Ari: “It’s maddening for me to sit in the pews listening to witnesses who have the most vague understanding of the issues at hand and are pontificating about what they think.” [05:03]

• On the rise of AI browsers:
  Ari: “What if you could have a conversation with your browser… summarize the opinions on this website about X… So many different ways it could enhance content-rich websites.” [12:49]

• On the future of video and AI:
  Ari: “I don’t think we’ve seen the end of innovation in the format of video people experience... AI can enable things that seem futuristic right now—like a personal shopper video that knows you.” [17:54]

• On the strategic rationale for the IAS buyout:
  Eric: “Take the thing private, really retool this for the AI era, likely do some acquisitions... [IAS is] an anchor for more acquisitions and it comes out as a different type of company.” [22:00]

• On the privacy-by-design approach in pharma data:
  Josh: “BranchLab’s whole mission is to take hyper-regulated data, lock it behind a neural net, never let it in or out... just deploy lightweight probability models.” [44:03]

• On the real public health impact of pharma ads:
  Josh: “Ethically, responsibly produced healthcare ads do not necessarily equal more drug sales—they equal more doctor visits... The more time a patient spends with their physician, health outcome improves mathematically.” [49:52]

• Lighthearted moment—Investor trips with Lance Armstrong:
  Ari: “Wait, are you serious, Eric? You going on a ride with Lance Armstrong?”
  Eric: “I mean, how could I say no, right?” [37:10]

Takeaways for Listeners

• Pharma advertising sits at the intersection of high regulation, privacy, and innovation: The market’s “specialist” status is justified both by compliance complexities and its scale.
• The future is privacy-by-design: As U.S. state laws tighten and the federal government considers national standards, neural nets and probabilistic models will be central to compliant pharma ads.
• Major AI and M&A moves are reshuffling the ad tech stack: The week’s news—Google’s steady AI rollouts, major acquisitions like IAS, and Nvidia’s OpenAI deal—signal a decisive shift to AI-driven infrastructure and measurement across verticals.
• Marketing and measurement remain key battlegrounds: The TTD-Axiom partnership and questions over DV360 vs. Trade Desk market share show innovation and integration are crucial for winning marketers’ budgets.
• Political winds may drive regulation, but outright pharma ad bans are unlikely: Expect more disclosure requirements and constraints on data usage, not prohibitions on ads themselves.

For a deeper dive into the nuances of pharma ad tech and the latest industry maneuvers, the interview with Josh Walsh provides an expert’s perspective rooted in technical detail and practical experience.

[End of Summary]